Promius Pharma LLC, a subsidiary of Dr Reddy’s Laboratories, announced today that ZEMBRACE SymTouch is now commercially available in the US.
The product is a pre-filled, low-dose, ready-to-use, 2-step auto injector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. Because it is a subcutaneous injection, it may lead to rapid relief of migraine, a press release said.
People suffering from migrane often have more than one kind of attack. Different types of medications can be used to treat different types of attacks.
“ZEMBRACE SymTouch is a welcome addition to the toolkit for acute treatment of migraine,” said Roger Cady, MD, Associate Executive Chairman of the National Headache Foundation.
“This 3-mg, easy-to-use subcutaneous injection of sumatriptan may be desired by many migraine patients who need a medication that can rapidly treat migraine attacks. Also, the 3-mg dose allows for up to four doses of the medicine in a 24-hour period, thus allowing dosing flexibility for patients.”
The product is available as a box of four auto injectors.